Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05905198
Other study ID # K3438
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 24, 2023
Est. completion date March 1, 2024

Study information

Verified date June 2023
Source Peking Union Medical College Hospital
Contact Yi Guo, M.D.
Phone 13910091280
Email guoyi@pumch.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Variable Frequency Stimulation(VFS) is a stimulation pattern applied in Deep Brain Stimulation(DBS) therapy for Parkinson's disease(PD). Peking Union Medical College Hospital was the first centre conducting research on VFS. The studies in the past have resembled conclusion that VFS provides improvement not only in the major symptoms such as tremor and rigidity, but also in gait and balance disorder. However, the best programming strategy of VFS has not met agreement. The random-controlled double blinded crossover study is designed for participants who underwent DBS surgery in bilateral subthalamic nucleus for parkinson's disease. The investigators study several strategies on programming and observe the improvement of symptom to look for the best one. A 4-month follow-up is designed to observe a relatively long-term effectiveness of VFS. The study intends to gather more clinical evidence to guide further studies on VFS application.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date March 1, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Idiopathic Parkinson's disease (according to the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease); - 18-75 years of age; - Hoehn & Yahr = 3 (in best OFF-medication condition); - Implanted bilateral subthalamic nucleus DBS for over 1 year; - gait Impairments in OFF-medication condition; - High Frequency Stimulation provides significant improvement; - in OFF-medication On-stimulation condition, capable of walking = 10m. Exclusion Criteria: - mental disorder or dementia; - Pregnant women, lactating mothers or women who are unable to take effective measures to prevent pregnancy; - With other diseases that can affect walking distance, such as joint diseases of the lower body, spinal diseases, neuropathy, or serious heart or lung diseases; - In severe health condition, such as diseases associated with heart or liver; - Epilepsy; - Lead off target; - Unable to willingly sign Written informed Consent; - Disagree or unable to cooperate with follow-up sessions.

Study Design


Intervention

Device:
Programming
programming the implanted DBS device to adjust the parameter and switch stimulation mode between Variable-Frequency settings and High-Frequency settings.

Locations

Country Name City State
China Peking Union Medical College Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline 5m-Timed Up and Go test Time Result at 2 months. Conduct a TUG test with 5m range setting and measure the time cost Baseline, 2 months
Primary Change from Baseline 5m-Timed Up and Go test Time Result at 4 months. Conduct a TUG test with 5m range setting and measure the time cost Baseline, 4 months
Secondary Change from Baseline 5m-Timed Up and Go test Step Frequency at 2 months. Conduct a TUG test with 5m range setting and measure the step movement and calculate the step frequency Baseline, 2 months
Secondary Change from Baseline 5m-Timed Up and Go test Step Frequency at 4 months. Conduct a TUG test with 5m range setting and measure the step movement and calculate the step frequency Baseline, 4 months
Secondary Change from Baseline 5m-Timed Up and Go test Length at 2 months. Conduct a TUG test with 5m range setting and measure the length of each step Baseline, 2 months
Secondary Change from Baseline 5m-Timed Up and Go test Step Length at 4 months. Conduct a TUG test with 5m range setting and measure the length of each step Baseline, 4 months
Secondary Change from Baseline 5m-Timed Up and Go test Step Variation Coefficient at 2 months. Conduct a TUG test with 5m range setting and use the length of each step to calculate the difference coefficient Baseline, 2 months
Secondary Change from Baseline 5m-Timed Up and Go test Step Variation Coefficient at 4 months. Conduct a TUG test with 5m range setting and use the length of each step to calculate the difference coefficient Baseline, 4 months
Secondary Change from Baseline Movement Disorder Society Unified Parkinson's Disease Rating Scale part III score at 2 months. Conduct a Movement Disorder Society Unified Parkinson's Disease Rating Scale survey and record the score. Higher MDS UPDRS III score represents worse movement disorder symptoms. Baseline, 2 months
Secondary Change from Baseline Movement Disorder Society Unified Parkinson's Disease Rating Scale part III score at 4 months. Conduct a Movement Disorder Society Unified Parkinson's Disease Rating Scale survey and record the score. Higher MDS UPDRS III score represents worse movement disorder symptoms. Baseline, 4 months
See also
  Status Clinical Trial Phase
Completed NCT02915848 - Long-term Stability of LFP Recorded From the STN and the Effects of DBS
Recruiting NCT03648905 - Clinical Laboratory Evaluation of Chronic Autonomic Failure
Terminated NCT02688465 - Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE). Phase 4
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Active, not recruiting NCT04006210 - Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations Phase 3
Completed NCT02562768 - A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease Phase 1
Completed NCT00105508 - Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia Phase 3
Completed NCT00105521 - Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia Phase 3
Recruiting NCT06002581 - Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease N/A
Completed NCT02236260 - Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation N/A
Completed NCT00529724 - Body Weight Gain, Parkinson, Subthalamic Stimulation Phase 2
Recruiting NCT05699460 - Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Completed NCT03703570 - A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations Phase 2
Completed NCT03462680 - GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures N/A
Completed NCT02837172 - Diagnosis of PD and PD Progression Using DWI
Not yet recruiting NCT04046276 - Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease N/A
Recruiting NCT02952391 - Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol N/A
Active, not recruiting NCT02937324 - The CloudUPDRS Smartphone Software in Parkinson's Study. N/A
Terminated NCT02924194 - Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease N/A
Completed NCT02939391 - A Study of KW-6356 in Subjects With Early Parkinson's Disease Phase 2